Antibacterial biotech Achaogen files for a $75 million IPO
Achaogen, which is developing antibacterials for the treatment of multi-drug resistant infections, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The South San Francisco, CA-based company, which was founded in 2002 and booked $16 million in grant revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol AKAO. Credit Suisse and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.